Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy on Anebulo Pharmaceuticals (NASDAQ:ANEB) and maintained an $8 price target.
October 03, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst has reiterated a Speculative Buy on Anebulo Pharmaceuticals and maintained an $8 price target.
The reiteration of a Speculative Buy rating and maintenance of an $8 price target by Benchmark analyst Robert Wasserman indicates a positive outlook for Anebulo Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100